| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8454776 | Lung Cancer | 2016 | 6 Pages |
Abstract
This post-hoc analysis illustrated real-life differences in patients with NSCLC prescribed platinum-based first-line treatment, and suggested that baseline patient and disease characteristics were associated with physician's choice of platinum agent, with cisplatin being more frequently prescribed to younger and fitter patients.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Egbert Smit, Denis Moro-Sibilot, Javier de Castro Carpeño, Krzysztof Lesniewski-Kmak, Joachim Aerts, Rosa Villatoro, Kees Kraaij, Karim Nacerddine, Yulia Dyachkova, Karen T. Smith, Allicia Girvan, Carla Visseren-Grul, Philipp A. Schnabel,